GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (NAS:ATRA) » Definitions » Shiller PE Ratio

Atara Biotherapeutics (Atara Biotherapeutics) Shiller PE Ratio : (As of Apr. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Atara Biotherapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Atara Biotherapeutics Shiller PE Ratio Historical Data

The historical data trend for Atara Biotherapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Shiller PE Ratio Chart

Atara Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Atara Biotherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Atara Biotherapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Atara Biotherapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atara Biotherapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Shiller PE Ratio falls into.



Atara Biotherapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Atara Biotherapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Atara Biotherapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.56/129.4194*129.4194
=-0.560

Current CPI (Dec. 2023) = 129.4194.

Atara Biotherapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.515 99.695 -0.669
201406 -0.232 100.560 -0.299
201409 -0.305 100.428 -0.393
201412 -0.670 99.070 -0.875
201503 -0.420 99.621 -0.546
201506 -0.620 100.684 -0.797
201509 -0.430 100.392 -0.554
201512 -0.750 99.792 -0.973
201603 -0.580 100.470 -0.747
201606 -0.660 101.688 -0.840
201609 -0.880 101.861 -1.118
201612 -0.630 101.863 -0.800
201703 -0.880 102.862 -1.107
201706 -0.940 103.349 -1.177
201709 -1.020 104.136 -1.268
201712 -1.150 104.011 -1.431
201803 -1.050 105.290 -1.291
201806 -1.150 106.317 -1.400
201809 -1.290 106.507 -1.568
201812 -1.750 105.998 -2.137
201903 -1.440 107.251 -1.738
201906 -1.600 108.070 -1.916
201909 -1.310 108.329 -1.565
201912 -1.360 108.420 -1.623
202003 -1.200 108.902 -1.426
202006 -1.140 108.767 -1.356
202009 -0.920 109.815 -1.084
202012 -0.950 109.897 -1.119
202103 -0.860 111.754 -0.996
202106 -0.910 114.631 -1.027
202109 -0.900 115.734 -1.006
202112 -0.960 117.630 -1.056
202203 -0.870 121.301 -0.928
202206 0.180 125.017 0.186
202209 -0.820 125.227 -0.847
202212 -0.720 125.222 -0.744
202303 -0.720 127.348 -0.732
202306 -0.680 128.729 -0.684
202309 -0.660 129.860 -0.658
202312 -0.560 129.419 -0.560

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Atara Biotherapeutics  (NAS:ATRA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Atara Biotherapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Atara Biotherapeutics (Atara Biotherapeutics) Business Description

Traded in Other Exchanges
Address
2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Executives
Jill Henrich officer: EVP, Global Head RA & Quality 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Pascal Touchon director, officer: President and CEO C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD SUITE 900, SOUTH SAN FRANCISCO CA 94080
Amar Murugan officer: SVP, GC & Secretary C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD,SUITE 900, SOUTH SAN FRANCISCO CA 94080
Eric J Hyllengren officer: SVP, CFO 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Anhco Nguyen officer: EVP, Chief Sci. & Tech Officer 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Manher Joshi officer: EVP, Chief Medical Officer 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Eric Dobmeier director C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
William K Heiden director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Charlene A. Banard officer: EVP, Chief Technical Officer C/O APPLIED MOLECULAR TRANSPORT INC., 450 EAST JAMIE COURT, SOUTH SAN FRANCISCO CA 94080
Jakob Dupont officer: EVP, Head of R&D C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Utpal Koppikar officer: Chief Financial Officer C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO CA 94080
Ameet Mallik director C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Kristin Yarema officer: Chief Commercial Officer C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080
Joe Newell officer: Chief Tech. Operations Officer C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO CA 94080